Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Telmisartan
Drug ID BADD_D02147
Description Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Indications and Usage Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
Marketing Status approved; investigational
ATC Code C09CA07
DrugBank ID DB00966
KEGG ID D00627
MeSH ID D000077333
PubChem ID 65999
TTD Drug ID D0N6RF
NDC Product Code 72606-506; 10695-139; 65841-805; 68462-199; 68462-200; 72606-507; 55111-095; 62135-536; 62135-537; 62332-089; 65162-293; 71209-049; 52286-0024; 53104-7624; 65404-007; 42291-792; 42571-226; 62135-535; 62332-087; 0597-0041; 72241-017; 65841-804; 65862-868; 68071-2591; 72241-015; 72241-016; 65372-1146; 42291-790; 46708-608; 53002-1794; 71335-1428; 71335-2173; 12666-0010; 50370-0015; 64220-124; 65862-727; 68554-0049; 42571-227; 43547-284; 43547-285; 53746-291; 63629-5682; 0378-2920; 67877-482; 68382-472; 68382-473; 70518-3556; 0597-0039; 65404-006; 66039-895; 71052-679; 45865-836; 53746-292; 65841-806; 65862-867; 68071-5178; 71335-1723; 57451-1206; 46708-610; 67877-483; 68788-8440; 68788-8441; 70518-3300; 0597-0040; 62512-0040; 64552-4026; 65015-845; 42291-791; 43547-283; 53746-293; 62332-088; 0378-2921; 65862-869; 67877-484; 68462-201; 70518-2572; 71209-050; 71209-051; 72606-508; 52562-009; 72761-021; 42571-228; 46708-609; 50090-5490; 63187-951; 0378-2922; 65162-291; 65162-292; 68382-471; 71335-2191; 62331-032; 64220-171
UNII U5SYW473RQ
Synonyms Telmisartan | 4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid | Pritor | BIBR 277 | BIBR-277 | Micardis
Chemical Information
Molecular Formula C33H30N4O2
CAS Registry Number 144701-48-4
SMILES CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thalamus haemorrhage17.08.01.062; 24.07.04.0330.000260%-
Gait inability08.01.02.011; 17.02.05.0690.000260%-
Hepatic cytolysis09.01.07.0360.000781%-
Hypertensive urgency24.08.01.005---
Injection site hypoaesthesia08.02.03.060; 12.07.03.060; 17.02.06.051---
Nasal flaring22.12.02.008---
Post micturition dribble20.02.02.0280.000521%-
Renal tubular dysfunction20.05.03.0280.000521%-
Sprue-like enteropathy07.17.01.014; 14.02.01.0110.001171%-
Therapeutic product effect incomplete08.06.01.0520.000390%-
Therapy non-responder08.06.01.0630.000521%-
Throat clearing22.12.03.0280.000260%-
Vulvovaginal inflammation21.14.02.014---
The 14th Page    First    Pre   14    Total 14 Pages